Anebulo Pharmaceuticals Inc.

ANEB | OTC

Price Alert Chart Builder DCF Calculator

$1.12

+$0.25 (+28.74%)

At close: Mar 18, 2026, 3:46 PM ET

Overview Rating Statistics Financials Earnings Ownership Profile

+28.74%

(1D)

Rating

Updated: Mar 14, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $45.68M

1D Range

0.87 1.12

52W Range

0.30 3.42

Valuation (TTM)

PE -5.33

PB 5.76

EV/EBITDA -4.40

Valuation (NTM)

Forward PE N/A

Forward PEG N/A

Price Target $6

Cash Flow

FCF Yield N/A

SBC Adj. FCF Yield N/A

SBC Impact -17.7%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y N/A | N/A

FCF 3Y | 5Y N/A | N/A

Returns

ROA -78.9%

ROE -67.8%

ROIC -89.9%

Financial Health

Net Cash

$9.04M

Current Ratio 17.34

Interest Coverage -26.70

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addic...

Sector Healthcare

Industry Biotechnology

Employees 2

IPO Date May 6, 2021

Website www.anebulo.com

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.